The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index, and 1 are not checked yet.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Open accessPublished version of a preprint
Abstract
The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein 1-5 show promise therapeutically and are being evaluated clinically 6-8. Here, to identify the structural correlates of SARS-CoV-2 neutralization, we solved eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed us to classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segment with short CDRH3 loops that block ACE2 and bind only to 'up' RBDs; (2) ACE2-blocking neutralizing antibodies that bind both up and 'down' RBDs and can contact adjacent RBDs; (3) neutralizing antibodies that bind outside the ACE2 site and recognize both up and down RBDs; and (4) previously described antibodies that do not block ACE2 and bind only to up RBDs 9. Class 2 contained four neutralizing antibodies with epitopes that bridged RBDs, including a VH3-53 antibody that used a long CDRH3 with a hydrophobic tip to bridge between adjacent down RBDs, thereby locking the spike into a closed conformation. Epitope and paratope mapping revealed few interactions with host-derived N-glycans and minor contributions of antibody somatic hypermutations to epitope contacts. Affinity measurements and mapping of naturally occurring and in vitro-selected spike mutants in 3D provided insight into the potential for SARS-CoV-2 to escape from antibodies elicited during infection or delivered therapeutically. These classifications and structural analyses provide rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use, and provide insight into immune responses against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical (Extended Data Table 3 and 4).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The T478K mutation in the RBD is unique to the Delta variant and falls within the epitope region of potent neutralizing monoclonal antibodies categorized as 'Class1' 17”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“As expected, plasma neutralizing activity was directly correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a–d).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Although circulating antibodies derived from plasma cells wane over time, long-lived immune memory can persist in expanded clones of memory B cells7,20.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“As seen in natural infection, a majority of the antibodies tested (9/17) were at least ten-fold less effective against pseudotyped viruses carrying the E484K mutation7,12,29.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In anti-RBD ELISAs the mean half-maximal effective concentration (EC50) was higher than that observed in infected individuals after 6.2 months but not significantly different from antibodies obtained 1.3 months after infection (Extended Data Fig. 6a, and Table 5 and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Consistent with the plasma neutralization results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-BioNTech and Moderna vaccinee antibodies were not significantly different from each other or to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after infection (Fig. 3a and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [23]
In the citing paper
“Residue S477 is close to the receptor binding site (Fig ED2) and part of the epitope recognized by the S2E12 and C102 neutralizing antibodies 17,18 .”
From Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (2021) · cites this paper as [17]
In the citing paper
“a potent Ab that can recognize both “up” and “down” SARS-CoV-2 RBD conformations [41].”
From Deep geometric representations for modeling effects of mutations on protein-protein binding affinity (2021) · cites this paper as [41]
In the citing paper
“Importantly, our spike did not contain R346K, which has been observed at relatively low frequency (<10%) within the Omicron lineage, but which is known to mediate escape from class 3 neutralizing monoclonal antibodies such as AZD1061/cilgavimab (Barnes et al., 2020; Dong et al., 2021; Greaney et al., 2021b).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Barnes et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Cited by
Sorted by citations
Items 401–500 of 1,004
High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
Tan, T. J. C., Mou, Z., Lei, R., Ouyang, W. O., Yuan, M., Song, G., Andrabi, R., Wilson, I. A., Kieffer, C., Dai, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37786-1 · Cited by 40
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Focosi, D., Casadevall, A., Franchini, M., & Maggi, F. (2024) · Viruses · doi:10.3390/v16020217 · Cited by 40
Flores-Alanis, A., Cruz‐Rangel, A., Rodríguez‐Gómez, F., González, J., Torres-Guerrero, C. A., Delgado, G., Cravioto, A., & Morales-Espinosa, R. (2021) · Pathogens · doi:10.3390/pathogens10020184 · Cited by 40
Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 40
Ubah, O. C., Lake, E. W., Gunaratne, G. S., Gallant, J. P., Fernie, M., Robertson, A. J., Marchant, J. S., Bold, T. D., Langlois, R. A., Matchett, W. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27611-y · Cited by 38
Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein
Tan, Z. W., Tee, W.-V., Samsudin, F., Guarnera, E., Bond, P. J., & Berezovsky, I. N. (2022) · Structure · doi:10.1016/j.str.2021.12.011 · Cited by 38
Uraki, R., Kiso, M., Imai, M., Yamayoshi, S., Ito, M., Fujisaki, S., Takashita, E., Ujie, M., Furusawa, Y., Yasuhara, A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01170-4 · Cited by 38
Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Javanmardi, K., Segall-Shapiro, T. H., Chou, C., Boutz, D. R., Olsen, R. J., Xie, X., Xia, H., Shi, P., Johnson, C. D., Annapareddy, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.016 · Cited by 39
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
Chen, W., Hajduczki, A., Martinez, E. J., Bai, H., Matz, H. C., Hill, T. M., Lewitus, É., Chang, W. C., Dawit, L., Peterson, C. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36106-x · Cited by 39
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35
Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design
Düzgüneş, N., Fernández‐Fuentes, N., & Konopka, K. (2021) · Pathogens · doi:10.3390/pathogens10121599 · Cited by 38
Hanke, L., Sheward, D. J., Pankow, A., Vidakovics, L. P., Karl, V., Kim, C., Urgard, E., Smith, N. L., Astorga-Wells, J., Ekström, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm0220 · Cited by 38
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
Huang, Q., Han, X., & Yan, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125348 · Cited by 37
Callaway, H., Hastie, K. M., Schendel, S. L., Li, H., Yu, X., Shek, J., Buck, T. K., Hui, S., Bedinger, D., Troup, C. B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112014 · Cited by 36
Xiao, H., Hu, J., Huang, C., Feng, W., Liu, Y., Kumblathan, T., Tao, J., Xu, J., Le, X. C., & Zhang, H. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117000 · Cited by 39
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
Fu, D. B., Zhang, G., Wang, Y., Zhang, Z., Hu, H., Shěn, S., Wu, J., Li, B., Li, X., Fang, Y., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001209 · Cited by 38
Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2
Gölcük, M., Yıldız, A., & Gür, M. (2022) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2022.108286 · Cited by 34
Spinello, A., Saltalamacchia, A., Borišek, J., & Magistrato, A. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c01415 · Cited by 32
Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens
Nuqui, X., Casalino, L., Zhou, L., Shehata, M., Wang, A., Tse, A. L., Ojha, A. A., Kearns, F. L., Rosenfeld, M. A., Miller, E. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50976-9 · Cited by 33
Garden, O. A., Reubi, J. C., Dykes, N. L., Yeager, A. E., McDonough, S. P., & Simpson, K. W. (2005) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2005.tb02678.x · Cited by 37
Liu, Z., Xu, W., Chen, Z., Fu, W., Zhan, W., Gao, Y., Zhou, J., Zhou, Y., Wu, J., Wang, Q., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00871-6 · Cited by 38
Lam, J. H., Khan, A. K., Cornell, T., Chia, T. W., Dress, R. J., Yeow, W. W. W., Mohd-Ismail, N. K., Venkataraman, S., Ng, K. T., Tan, Y., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c01243 · Cited by 36
Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 37
Shi, Y., Huang, J., Liu, Y., Liu, J., Guo, X., Li, J., Gong, L., Zhou, X., Cheng, G., Qiu, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo1827 · Cited by 36
Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine
Wu, Y., Wang, S., Zhang, Y., Yuan, L., Zheng, Q., Wei, M., Shi, Y., Wang, Z., Ma, J., Wang, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.011 · Cited by 35
Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
Misson, L., Liu, H., Ozorowski, G., Tran, Q., Woehl, J. L., Khalek, I. S., Smith, J., Barman, S., Zhao, F., Keating, C., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216612120 · Cited by 36
A Review of Machine Learning and Algorithmic Methods for Protein Phosphorylation Site Prediction
Esmaili, F., Pourmirzaei, M., Ramazi, S., Shojaeilangari, S., & Yavari, E. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.03.007 · Cited by 37
SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly
Vester, S. K., Rahikainen, R., Anuar, I. N. A. K., Hills, R. A., Tan, T. K., & Howarth, M. R. (2022) · Nature Communications · doi:10.1038/s41467-022-31193-8 · Cited by 35
Braet, S. M., Buckley, T. S., Venkatakrishnan, V., Dam, K.-M. A., Björkman, P. J., & Anand, G. S. (2023) · eLife · doi:10.7554/elife.82584 · Cited by 36
Self-citationInsights on the mutational landscape of the SARS-CoV-2 Omicron variantPreprint
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.06.471499 · Cited by 35
Ying, B., Scheaffer, S. M., Whitener, B. M., Liang, C.-Y., Dmytrenko, O., Mackin, S., Wu, K., Lee, D. W., Avena, L. E., Chong, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.479419 · Cited by 35
Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 31
Cheng, L., Song, S., Zhou, B., Ge, X., Yu, J., Zhang, M., Ju, B., & Zhang, Z. (2021) · Virology Journal · doi:10.1186/s12985-021-01554-8 · Cited by 32
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
Ferrara, F., Erasmus, M. F., D’Angelo, S., Leal‐Lopes, C., Teixeira, A. A. R., Choudhary, A. K., Honnen, W. J., Calianese, D. C., Huang, D., Peng, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27799-z · Cited by 36
Innate Immune Response in SARS-CoV-2 Infection
Schiuma, G., Beltrami, S., Bortolotti, D., Rizzo, S., & Rizzo, R. (2022) · Microorganisms · doi:10.3390/microorganisms10030501 · Cited by 39
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., & Tafesse, F. (2022) · iScience · doi:10.1016/j.isci.2022.103960 · Cited by 31
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A. R., VanBlargan, L. A., Binshtein, E., Chen, R. E., Case, J. B., Kramer, K. J., Armstrong, E., Myers, L., Trivette, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159062 · Cited by 31
A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 32
Engineered disulfide reveals structural dynamics of locked SARS-CoV-2 spike
Qu, K., Chen, Q., Ciazynska, K. A., Liu, B., Zhang, X., Wang, J., He, Y., Guan, J., He, J., Liu, T., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010583 · Cited by 33
Halfmann, P., Minor, N. R., Haddock, L. A., Maddox, R., Moreno, G. K., Braun, K. M., Baker, D. A., Riemersa, K. K., Prasad, A., Alman, K. J., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac104 · Cited by 36
Korenkov, M., Zehner, M., Cohen‐Dvashi, H., Borenstein-Katz, A., Kottege, L., Janicki, H., Vanshylla, K., Weber, T., Gruell, H., Koch, M., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.004 · Cited by 36
Maltseva, M., Keeshan, A., Cooper, C., & Langlois, M. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2384192 · Cited by 34
Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2
Zhu, L., Deng, Y., Zhang, R.-R., Cui, Z., Sun, C.-Y., Fan, C., Xing, X., Huang, W., Chen, Q., Zhang, N.-N., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa297 · Cited by 34
Du, S., Liu, P., Zhang, Z., Xiao, T., Yasimayi, A., Huang, W., Wang, Y., Cao, Y., Xie, X. S., & Xiao, J. (2021) · Cell Research · doi:10.1038/s41422-021-00555-0 · Cited by 34
Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 33
ESC: a comprehensive resource for SARS-CoV-2 immune escape variants
Rophina, M., Pandhare, K., Shamnath, A., Imran, M., Jolly, B., & Scaria, V. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab895 · Cited by 33
Simnani, F. Z., Singh, D., & Kaur, R. (2021) · 3 Biotech · doi:10.1007/s13205-021-03076-0 · Cited by 35
Ju, B., Zheng, Q., Guo, H., Fan, Q., Li, T., Song, S., Sun, H., Shen, S., Zhou, X., Cheng, L., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00638-6 · Cited by 37
Mader, A.-L., Tydykov, L., Glück, V., Bertok, M., Weidlich, T., Gottwald, C., Stefl, A., Vogel, M., Plentz, A., Köstler, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104076 · Cited by 33
Wang, S., Sun, H., Zhang, Y., Yuan, L., Wang, Y., Zhang, T., Wang, S., Zhang, J., Yu, H. J., Xiong, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110862 · Cited by 30
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
He, W., Yuan, M., Callaghan, S., Musharrafieh, R. G., Song, G., Silva, M., Beutler, N., Lee, W.-H., Yong, P., Torres, J. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9605 · Cited by 32
Zhou, X., Ma, F., Xie, J., Yuan, M., Li, Y., Shaabani, N., Zhao, F., Huang, D., Wu, N. C., Lee, C.-C. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109109 · Cited by 31
Single domain shark VNAR antibodies neutralize SARS‐CoV‐2 infection in vitro
Gauhar, A., Privezentzev, C. V., Demydchuk, M., Gerlza, T., Rieger, J., Kungl, A. J., Walsh, F. S., Rutkowski, J. L., & Stocki, P. (2021) · The FASEB Journal · doi:10.1096/fj.202100986rr · Cited by 30
SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
Yang, L., Li, J., Guo, S., Hou, C., Liao, C., Shi, L., Ma, X., Jiang, S., Zheng, B., Fang, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212114 · Cited by 35
Reyes, R. A., Clarke, K., Gonzales, S. J., Cantwell, A. M., Garza, R., Catano, G., Tragus, R. E., Patterson, T. F., Bol, S. M., & Bunnik, E. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261656 · Cited by 33
Chevillard, C., Amen, A., Besson, S., Hannani, D., Bally, I., Dettling, V., Gout, E., Moreau, C., Buisson, M., Gallet, S., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.011 · Cited by 35
Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer
Wright, D. W., Harvey, W. T., Hughes, J., Cox, M., Peacock, T. P., Colquhoun, R., Jackson, B., Orton, R. J., Nielsen, M., Hsu, S. N., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac023 · Cited by 31
Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids
Spitalieri, P., Centofanti, F., Murdocca, M., Scioli, M. G., Latini, A., Cesare, S. D., Citro, G., Rossi, A., Orlandi, A., Miersch, S., et al. (2022) · Cells · doi:10.3390/cells11071235 · Cited by 31
Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30
Fang, Y., Sun, P., Xie, X., Du, M., Du, F., Ye, J., Kalveram, B., Plante, J. A., Plante, K. S., Li, B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9962 · Cited by 30
Muik, A., Lui, B. G., Quandt, J., Diao, H., Fu, Y., Bacher, M., Gordon, J., Toker, A., Grosser, J., Ozhelvaci, O., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112888 · Cited by 37
Liu, L., Casner, R. G., Guo, Y., Wang, Q., Iketani, S., Chan, J. F., Yu, J., Dadonaite, B., Nair, M. S., Mohri, H., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.003 · Cited by 42
Li, L., Chen, X., Wang, Z., Li, Y., Wang, C., Jiang, L., & Zuo, T. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011856 · Cited by 30
Liu, B., Yin, Y., Liu, Y., Wang, T., Sun, P., Ou, Y., Gong, X., Hou, X., Zhang, J., Ren, H., et al. (2021) · Engineering · doi:10.1016/j.eng.2021.06.012 · Cited by 31
The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein
Girt, G. C., Lakshminarayanan, A., Huo, J., Dormon, J., Norman, C. S., Afrough, B., Harding, A. C., James, W., Owens, R. J., & Naismith, J. H. (2021) · Royal Society Open Science · doi:10.1098/rsos.211016 · Cited by 33
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 38
RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
Liang, Q., Wang, Y., Zhang, S., Sun, J., Sun, W., Li, J., Liu, Y., Li, M., Cheng, L., Jiang, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104043 · Cited by 31
Abebe, E. C., Medhin, M. T. G., T/Mariam, A. B., Dejenie, T. A., Ayele, T. M., Admasu, F. T., Muche, Z. T., & Adela, G. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s360103 · Cited by 31
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Greaney, A. J., Kim, C., Kim, S., Hanke, L., Hyllner, E., Dyrdak, R., Lee, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101577 · Cited by 31
Cheng, Z., Elmes, M. J., Kirkup, S. E., Abayasekara, D. R. E., & Wathes, D. C. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1820249 · Cited by 31
Datta, S. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13102877 · Cited by 31
Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serumPreprint
Tuekprakhon, A., Huo, J., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.21.492554 · Cited by 31
Jensen, J. L., Sankhala, R. S., Dussupt, V., Bai, H., Hajduczki, A., Lal, K. G., Chang, W. C., Martinez, E. J., Peterson, C. E., Golub, E. S., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01596-22 · Cited by 29
Zhao, X., Qiu, T., Huang, X., Mao, Q., Wang, Y., Qiao, R., Li, J., Mao, T., Wang, Y., Cun, Y., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00648-1 · Cited by 30
Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30
Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
Xu, S., Wang, Y., Wang, Y., Zhang, C., Qin, H., Gu, C., Xu, R., Wang, T., Yang, Y. P., Zang, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2024455 · Cited by 28
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
Andreano, E., Paciello, I., Marchese, S., Donnici, L., Pierleoni, G., Piccini, G., Manganaro, N., Pantano, E., Abbiento, V., Pileri, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31115-8 · Cited by 30
Wang, Y., Yan, A., Song, D., Duan, M., Dong, C., Chen, J., Jiang, Z., Gao, Y., Rao, M., Feng, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45050-3 · Cited by 29
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
Liu, C., Zhou, D., Dijokaite-Guraliuc, A., Supasa, P., Duyvesteyn, H. M. E., Ginn, H. M., Selvaraj, M., Mentzer, A. J., Das, R., de Silva, T. I., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101553 · Cited by 28
Structural basis of Omicron neutralization by affinity-matured public antibodiesPreprint
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G. M., Albert, J., Murrell, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.03.474825 · Cited by 27
Structural understanding of SARS-CoV-2 virus entry to host cells
Le, K. P. U., Kannappan, S., Kim, T., Lee, J. H., Lee, H.-R., & Kim, K. K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1288686 · Cited by 34
Structural Immunology of SARS ‐ CoV ‐2
Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
Cohen, A. A., Gnanapragasam, P. N. P., Lee, Y. E., Hoffman, P. R., Ou, S. K.-H., Kakutani, L. M., Keeffe, J. R., Wu, H., Howarth, M. R., West, A. P., et al. (2021) · CaltechAUTHORS (California Institute of Technology) · Cited by 29
Self-citationHumoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30
Buchan, S. A., Tibebu, S., Daneman, N., Whelan, M., Vanniyasingam, T., Murti, M., & Brown, K. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab496 · Cited by 31
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2
Castonguay, N., Zhang, W., & Langlois, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.676314 · Cited by 28
Casasnovas, J. M., Margolles, Y., Noriega, M. A., Guzmán, M. Á., Arranz, R., Melero, R., Casanova, M., Sánchez, J. A. C., de Oya, N. J., Gastaminza, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863831 · Cited by 30
Jacobsen, E., Fabricius, D., Class, M., Topfstedt, F., Lorenzetti, R., Janowska, I., Schmidt, F., Staniek, J., Zernickel, M., Stamminger, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35055-1 · Cited by 29
Structure-activity relationships of B.1.617 and other SARS-CoV-2 spike variantsPreprint
Yang, T., Yu, P., Chang, Y., Chang, N.-E., Tsai, Y.-X., Liang, K.-H., Drączkowski, P., Lin, B., Wang, Y., Chien, Y.-C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.12.459978 · Cited by 30
Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery
Onigbinde, S. B., Adeniyi, M., Daramola, O. E., Chukwubueze, F. M., Bhuiyan, M. M. A. A., Nwaiwu, J. I., Bhattacharjee, T., & Mechref, Y. S. (2025) · Biomedicines · doi:10.3390/biomedicines13082034 · Cited by 36
Phylogenetic analysis of SARS‐CoV‐2 in the first few months since its emergence
Pereson, M. J., Mojsiejczuk, L. N., Martínez, A. P., Flichman, D., Garcia, G. H., & Lello, F. A. D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26545 · Cited by 29
Kaku, Y., Kuwata, T., Zahid, H. M., Hashiguchi, T., Noda, T., Kuramoto, N., Biswas, S., Matsumoto, K., Shimizu, M., Kawanami, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109385 · Cited by 26
VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes
Sun, Q., Shu, C., Shi, W., Luo, Y., Fan, G., Nie, J., Bi, Y., Wang, Q., Qi, J., Lü, J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab921 · Cited by 28
An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies
Spicuzza, L., Campagna, D., Maria, C. D., Sciacca, E., Mancuso, S., Vancheri, C., & Sambataro, G. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023020 · Cited by 30
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27
Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development
Magazine, N., Zhang, T., Bungwon, A. D., McGee, M. C., Wu, Y., Veggiani, G., & Huang, W. (2024) · ImmunoHorizons · doi:10.4049/immunohorizons.2400003 · Cited by 32
Yao, X., Kong, L., Qiao, Y., Brand, D. D., Li, J., Yan, Z., Zheng, S. G., Qian, Y., & Fan, C. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101791 · Cited by 28
Designed mosaic nanoparticles enhance cross-reactive immune responses in mice
Wang, E. J. D., Cohen, A. A., Caldera, L. F., Keeffe, J. R., Rorick, A. V., Adia, Y. M., Gnanapragasam, P. N. P., Björkman, P. J., & Chakraborty, A. K. (2025) · Cell · doi:10.1016/j.cell.2024.12.015 · Cited by 29
Ansariniya, H., Seifati, S. M., Zaker, E., & Zare, F. (2021) · BioMed Research International · doi:10.1155/2021/8870425 · Cited by 27
Metadata
- Authors
- Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., Nussenzweig, M. C., West, A. P., & Bjorkman, P. J.
- Affiliations
- California Institute of Technology (US)
- Institute for Research in Biomedicine (CH)
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2020-10-12
- Volume
- 588
- Issue
- 7839
- Pages
- 682-687
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8092461
- OpenAlex
- W3092403777
- Cited by
- 1,599
- References
- 70
- Citations by year
- 2026: 94 · 2025: 121 · 2024: 181 · 2023: 267 · 2022: 448 · 2021: 440 · 2020: 35
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-02)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- U.S. Department of Energy (P41GM103393, DE-AC02-)
- Burroughs Wellcome Fund
- George Mason University
- California Institute of Technology
- Wellcome Trust
- National Institutes of Health (AI138938, P01 AI138938-S1, AI150464)
- Office of Science (P41GM103393, DE-AC02)
- Beckman Institute, California Institute of Technology
- National Institute of General Medical Sciences (AI150464, P41GM103393)
- National Institute of Allergy and Infectious Diseases (P50AI150464, F30AI147579, P01AI138938)
- Basic Energy Sciences (DE-AC02, P41GM103393)
- Biological and Environmental Research (P41 GM103393)
- SLAC National Accelerator Laboratory (P41GM103393)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, spike protein receptor-binding domain, antibody-antigen complex structure, ACE2 receptor, epitope mapping, N-glycans, somatic hypermutation, antibody escape, avidity, antibody combination therapy, spike trimer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
